Bionano Genomics, Inc. - BNGO STOCK NEWS

Bionano Genomics announced a peer-reviewed study showcasing its Optical Genome Mapping (OGM) as a superior method for analyzing acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The research, published in the International Journal of Cancer, found that OGM detected 31% more European Leukemia Net abnormalities and 35% more cases than traditional methods like karyotyping and FISH. Moreover, OGM's cost-effectiveness was highlighted, equating to two FISH probes.

CEO Erik Holmlin emphasized OGM's potential in routine diagnostics, aiming for improved clinical outcomes.

Bionano Genomics, Inc. (BNGO) announced the appointment of Helene Klein as its chief people officer on February 14, 2022. This strategic move aims to enhance the company's leadership and maintain a strong organizational culture during its expansion. Klein, who previously served at Beachbody Company, brings 14 years of experience where she significantly grew the workforce and revenue. At Bionano, she will lead human resources and drive diversity, equity, and inclusion initiatives to support the company's growth.

Bionano Genomics announced a novel workflow using optical genome mapping (OGM) that achieves a 93% success rate in analyzing fetal tissue, significantly higher than the 9.6% success rate of traditional methods like karyotyping (KT). This innovative approach eliminates the need for cell culture, addresses common failures in POC sample analysis, and enhances the identification of genetic abnormalities. The study's findings, published in medRXiv, indicate OGM can improve outcomes for parents facing pregnancy loss.

Bionano Genomics (BNGO) has announced that Erik Holmlin, PhD, its CEO, will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 2:30 pm ET. The event is tailored for BTIG clients. Bionano specializes in optical genome mapping solutions and offers N_xClinical™, a leading genomic data software. Their mission is to enhance genome visibility through innovative solutions and diagnostic services, including applications in clinical research and autism spectrum disorder diagnostics.

Bionano Genomics (BNGO) announced the adoption of its Saphyr system by two genetics laboratory hubs in the UK's National Health Service (NHS) - Newcastle upon Tyne and Birmingham Women’s and Children’s Trusts. This adoption aims to evaluate optical genome mapping (OGM) versus traditional cytogenetic methods, enhancing BNGO's presence in the UK market. Previous placements in Belfast and London underscore growing interest. The OGM's potential lies in improving efficiency and detection capabilities for hematologic malignancies and other conditions, as mentioned by NHS leaders.

Bionano Genomics (BNGO) announced a study demonstrating the enhanced performance of combining optical genome mapping (OGM) with a 523-gene NGS panel for evaluating myeloid tumors. This method exhibited superior sensitivity, accuracy, and the ability to detect novel variants compared to traditional cytogenetic techniques, including karyotyping and FISH. The research, led by Dr. Ravindra Kolhe, achieved 100% analytical concordance with conventional methods and identified additional structural variants and copy number variations. The findings support the combined OGM and NGS workflow as a cost-effective solution for comprehensive genomic profiling.

Bionano Genomics (BNGO) announced a groundbreaking study highlighting the use of Optical Genome Mapping (OGM) to identify rare genomic structural variants (SVs) linked to severe COVID-19. The research revealed that 17% of severely ill COVID-19 patients exhibited SVs affecting critical genes related to immune response and viral replication. This study, published in iScience, marks the first systematic investigation of SVs in COVID-19 severity, potentially enhancing understanding of genetic predispositions to severe disease. Bionano's OGM could play a pivotal role in future genomic research.

Bionano Genomics (BNGO) has pledged financial support to the ACMG Foundation for Genetic and Genomic Medicine's Next Generation Fellowship & Residency Training Awards Program. This initiative aims to address the shortage of qualified medical professionals in genetic and genomic medicine, helping to train new specialists over the next three years. Dr. Max Muenke emphasized the importance of Bionano's commitment, which contributes significantly to expanding the workforce in laboratory genetics. Bionano's President, Erik Holmlin, highlighted the company's mission to improve genome understanding and patient care.

Bionano Genomics (BNGO) has announced a three-year financial commitment to support the ACMG Foundation for Genetic and Genomic Medicine's Next Generation Fellowship & Residency Training Awards Program. This initiative aims to address the shortage of qualified genetic and genomics specialists, providing essential training to new professionals in the field. The ACMGF and its program have been pivotal in enhancing workforce capabilities for over two decades. Bionano's support underscores its commitment to advancing clinical genomics and improving patient access to specialized care.